Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab for prevention and mitigation of delayed graft function after kidney transplantation (high-risk adults, China)
CTR20255061Phase 3Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ravulizumab in end-stage kidney disease (ESKD), delayed graft function (DGF), sponsored by Alexion Pharmaceuticals. Started Mar 2026; status: active.
02
Drugs
ravulizumab
03
Conditions
end-stage kidney disease (ESKD)delayed graft function (DGF)
Beyond the preview
Go deeper on CTR20255061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255061.